It should be noted that most of the population in Mexico has an economical access barrier for acquiring osimertinib, which renders first and second generation TKIs as the most frequently used drugs to treat patients with EGFR-mutated NSCLC in our country. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.